Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion

Research output: Contribution to journalReviewpeer-review

  1. PREVALENCE OF SARS-COV-2-ANTIBODIES IN DANISH CHILDREN AND ADULTS

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A qualitative study of adolescent cancer survivors perspectives on social support from healthy peers - A RESPECT study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Home-based cognitive behavioural therapy for families of young children with cancer (FAMOS): A nationwide randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. National, clinical cohort study of late effects among survivors of acute lymphoblastic leukaemia: the ALL-STAR study protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Insufficient exposure to asparaginase therapy is a barrier to optimal treatment and survival in childhood acute lymphoblastic leukaemia (ALL). Three important reasons for inactivity or discontinuation of asparaginase therapy are infusion related reactions (IRRs), pancreatitis and life-threatening central nervous system (CNS). For IRRs, real-time therapeutic drug monitoring (TDM) and premedication are important aspects to be considered. For pancreatitis and CNS thrombosis one key question is if patients should be re-exposed to asparaginase after their occurrence.An expert panel met during the Congress of the International Society for Paediatric Oncology in Lyon in October 2019 to discuss strategies for diminishing the impact of these three toxicities. The panel agreed that TDM is particularly useful for optimising asparaginase treatment and that when a tight pharmacological monitoring programme is established premedication could be implemented more broadly to minimise the risk of IRR. Re-exposure to asparaginase needs to be balanced against the anticipated risk of leukemic relapse. However, more prospective data are needed to give clear recommendations if to re-expose patients to asparaginase after the occurrence of severe pancreatitis and CNS thrombosis.

Original languageEnglish
JournalESMO Open
Volume5
Issue number5
Pages (from-to)e000977
ISSN2059-7029
DOIs
Publication statusPublished - Sep 2020

ID: 62316056